PhRMA Points To Key Areas Where Transparency Could Be Hiked In Drug Negotiations

Updated Story After CMS signaled it hopes to improve transparency in the Medicare drug price negotiation program, the Pharmaceutical Research and Manufacturers of America (PhRMA) pointed Inside Health Policy to key areas the brand drug lobby has suggested in past comments where the agency could enhance its transparency efforts. The pharmaceutical lobby group tells IHP transparency could be improved in the agency’s application of the bona fide marketing standard to determine when generic competition is available,...